Cystinuria is an autosomal recessive disorder of renal tubular and intestinal transport of dibasic amino acids, which results in increased urinary excretion of cystine, and dibasic amino acids, such as ornithine, lysine and arginine (COLA). However, in this disease some heterozygous carriers have an autosomal dominant inheritance with incomplete penetrance.
It is classified as type A if mutations are found in both SLC3A1 alleles, type B if mutations are found in both SLC7A9 alleles, and putative type AB if one mutation is found in each gene. Heterozygous type AB individuals have been identified, but cystinuric patients from families of such individuals have two mutated alleles in the same gene in addition to a mutated allele in the other gene (that is, AAB and BBA ‘types’).
Early and correct diagnosis is essential for successful treatment of cystinuric patients. Assessment in stone formers includes medical history, imaging, and stone analysis and laboratory investigations. This disease should be suspected in patients younger than 30 years with recurrent, large or bilateral stones, and in patients having siblings with stone disease. It Should also be suspected if a sulfur odor is noticed during laser lithotripsy. Diagnosis is established primarily by stone analysis and/or quantitative 24 h urine analysis.
Get FREE sample copy at:
The Cystinuria market report also covers emerging drugs, current treatment practices, Cystinuria market share of the individual therapies, current and forecasted Cystinuria Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Cystinuria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Cystinuria Market Key Facts
The total cases of Cystinuria in the 7MM was found to be 85,876 in 2017.
The estimated population of Cystinuria in the United States was 32,548 in 2017.
Among the EU5 countries, Germany had the highest prevalent population of Cystinuria followed by France. On on the other hand, Spain had the lowest prevalent population.
The Cystinuria is found to be more prevalent in females as compared to males. In 2017, there were 17,381 prevalent cases of Cystinuria in females and 15,168 prevalent cases in males in the United States and as per DelveInsight’s analysts’ assessments, in both the genders, have the same trend as seen in all the countries of 7MM.
In type specific cases, maximum cases belong to Type B Cystinuria with 47% cases, while in Europe Type A is found to be more prevalent, while in Japan about 85.9% of cases belong to Type B Cystinuria.
Key Benefits of Cystinuria Market Report
Cystinuria market report provides an in-depth analysis of Cystinuria Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Cystinuria market report will help in developing business strategies by understanding the Cystinuria Market trends & developments, key players and future market competition that will shape and drive the Cystinuria market in the upcoming years.
The Cystinuria market report covers Cystinuria current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Cystinuria market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Cystinuria market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Cystinuria market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Cystinuria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Cystinuria epidemiology section covers insights about historical and current Cystinuria patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Cystinuria Drugs Uptake and Key Market Players
The Cystinuria Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cystinuria market or expected to get launched in the market during the study period. The analysis covers Cystinuria market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key companies are working on developing therapies for Cystinuria includes:
And many others.
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Cystinuria Competitive Intelligence Analysis
4. Cystinuria Market Overview at a Glance
5. Cystinuria Disease Background and Overview
6. Cystinuria Patient Journey
7. Cystinuria Epidemiology and Patient Population
8. Cystinuria Treatment Algorithm, Current Treatment, and Medical Practices
9. Cystinuria Unmet Needs
10. Key Endpoints of Cystinuria Treatment
11. Cystinuria Marketed Products
12. Cystinuria Emerging Therapies
13. Cystinuria Seven Major Market Analysis
14. Attribute Analysis
15. Cystinuria Market Outlook (7 major markets)
16. Cystinuria Access and Reimbursement Overview
17. KOL Views on the Cystinuria Market.
18. Cystinuria Market Drivers
19. Cystinuria Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Cystinuria Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Cystinuria in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Cystinuria Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cystinuria market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States